Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Alper Tuğral, Assoc.Prof
CONTACT
Gözde Kaya Uçar, Assist.Prof
CONTACT
Lead
Izmir Bakircay University
With
A total of 78 patients with NSCLC receiving active immunotherapy and meeting the predefined eligibility criteria will be enrolled. Participants assigned to the intervention group will perform supervised aerobic exercise on a cycle ergometer twice weekly for 24 weeks. Each session will consist of 5 minutes of warm-up, 30 minutes of aerobic exercise, and 5 minutes of cool-down. Exercise intensity will be prescribed based on estimated maximal oxygen consumption (VO₂max) and progressively increased from 60% during weeks 1-6 to 65% during weeks 7-12, 70% during weeks 13-18, and 75% during weeks 19-24. The exercise program will be implemented in accordance with the American College of Sports Medicine (ACSM) recommendations for exercise oncology. Assessments will be performed at baseline, 12 weeks, and at the end of 24 weeks. The primary outcomes will be immune system- and tumor microenvironment-related biomarkers which will be analyzed via ELISA system (CXCL9, CXCL11, CCL2, CCL5, IFN gamma and IL-10). Immune cells (NK cells, T and B lymphocytes, CD3+, CD4+, CD8+, CD19+, CD16/56+) will also be analyzed via flow-cytometry. Secondary outcomes will include handgrip strength, peripheral muscle strength, quality of life, fatigue, and cardiorespiratory capacity. Progression-free survival will also be evaluated as an exploratory clinical outcome. This study aims to provide prospective evidence regarding the potential immunomodulatory and tumor-related effects of structured aerobic exercise during active immunotherapy and to contribute to the development of individualized supportive exercise strategies for patients with NSCLC.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
